JP2014505658A - 癌を治療する方法 - Google Patents

癌を治療する方法 Download PDF

Info

Publication number
JP2014505658A
JP2014505658A JP2013537854A JP2013537854A JP2014505658A JP 2014505658 A JP2014505658 A JP 2014505658A JP 2013537854 A JP2013537854 A JP 2013537854A JP 2013537854 A JP2013537854 A JP 2013537854A JP 2014505658 A JP2014505658 A JP 2014505658A
Authority
JP
Japan
Prior art keywords
ras
cancer
compound
mutation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013537854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505658A5 (enExample
Inventor
マヌエル、カルロス、アルベス‐アイバド
ゴータム、ボーサカー
タパン、エム．カディア
ハゴプ、エム．カンタージャン
シルビー、ラケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2014505658A publication Critical patent/JP2014505658A/ja
Publication of JP2014505658A5 publication Critical patent/JP2014505658A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013537854A 2010-11-05 2011-11-04 癌を治療する方法 Pending JP2014505658A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41056010P 2010-11-05 2010-11-05
US61/410,560 2010-11-05
US42271510P 2010-12-14 2010-12-14
US61/422,715 2010-12-14
PCT/US2011/059285 WO2012061683A2 (en) 2010-11-05 2011-11-04 Methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2014505658A true JP2014505658A (ja) 2014-03-06
JP2014505658A5 JP2014505658A5 (enExample) 2014-12-18

Family

ID=46025128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537854A Pending JP2014505658A (ja) 2010-11-05 2011-11-04 癌を治療する方法

Country Status (4)

Country Link
US (1) US20130217710A1 (enExample)
EP (1) EP2635286A4 (enExample)
JP (1) JP2014505658A (enExample)
WO (1) WO2012061683A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
JP2024531386A (ja) * 2021-08-20 2024-08-29 合肥中科普瑞昇生物医▲薬▼科技有限公司 ヒト初代急性骨髄性白血病細胞用の培養培地及び培養方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068339A2 (en) * 2010-11-17 2012-05-24 Glaxosmithkline Llc Methods of treating cancer
HK1206611A1 (en) * 2012-05-31 2016-01-15 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
CA2879252C (en) 2012-08-17 2017-10-10 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
BR112015016559A2 (pt) * 2013-01-09 2017-07-11 Glaxosmithkline Ip No 2 Ltd combinação
US20160058751A1 (en) * 2013-03-28 2016-03-03 Cellworks Group, Inc. Composition and method for treating cancer
US9572828B2 (en) * 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
WO2015066439A2 (en) * 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating hematological malignancies
CN107148481A (zh) 2014-07-14 2017-09-08 苏黎世大学医学与自然科学院 用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
MX2022013430A (es) * 2020-04-27 2022-11-14 Verastem Inc Metodos para tratar el crecimiento celular anormal.
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
KR20250151412A (ko) 2023-01-26 2025-10-21 아비나스 오퍼레이션스, 인코포레이티드 세레블론계 kras 분해 단백질 및 이와 관련된 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501631A (ja) * 2004-06-11 2008-01-24 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
JP2008514635A (ja) * 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
WO2009018238A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
WO2009137391A2 (en) * 2008-05-06 2009-11-12 Smithkline Beecham Corporation Benzene sulfonamide thiazole and oxazole compounds
WO2010006225A1 (en) * 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
ES2527625T3 (es) * 2009-09-23 2015-01-27 Glaxosmithkline Llc Combinación farmacéutica
AU2010306653B2 (en) * 2009-10-16 2013-10-24 Novartis Ag Combination

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501631A (ja) * 2004-06-11 2008-01-24 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
JP2008514635A (ja) * 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
WO2009018238A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
WO2009137391A2 (en) * 2008-05-06 2009-11-12 Smithkline Beecham Corporation Benzene sulfonamide thiazole and oxazole compounds
WO2010006225A1 (en) * 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER INVESTIGATION, vol. 27, JPN6014051269, 2009, pages 273 - 285, ISSN: 0003159087 *
CANCER RES, vol. 67, no. 23, JPN6014051267, 2007, pages 11300 - 11308, ISSN: 0003159086 *
CANCER RESEARCH, vol. 69, no. 10, JPN6015038099, 2009, pages 4286 - 4293, ISSN: 0003159085 *
CURR HEMATOL MALIG REP, vol. 5, JPN6015038100, August 2010 (2010-08-01), pages 207 - 212, ISSN: 0003159089 *
NAT MED, vol. 14, no. 12, JPN6014051273, 2008, pages 1351 - 1356, ISSN: 0003159088 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024531386A (ja) * 2021-08-20 2024-08-29 合肥中科普瑞昇生物医▲薬▼科技有限公司 ヒト初代急性骨髄性白血病細胞用の培養培地及び培養方法
JP7800955B2 (ja) 2021-08-20 2026-01-16 合肥中科普瑞昇生物医▲薬▼科技有限公司 ヒト初代急性骨髄性白血病細胞用の培養培地及び培養方法
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
GB2629956A (en) * 2022-01-27 2024-11-13 Univ Tohoku Therapeutic agent for cancer

Also Published As

Publication number Publication date
WO2012061683A2 (en) 2012-05-10
EP2635286A4 (en) 2014-11-12
WO2012061683A3 (en) 2013-11-14
EP2635286A2 (en) 2013-09-11
US20130217710A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
JP2014505658A (ja) 癌を治療する方法
KR102708679B1 (ko) 나노입자 조성물에 대한 바이오마커
JP2022017495A (ja) 癌を治療するための併用療法
EP2643001A1 (en) Method of treating cancer
JP2021508704A (ja) がんを処置する方法
JP2013545757A (ja) 癌の治療方法
KR20150132205A (ko) B-Raf 억제제와 제2 억제제를 포함하는 조합 요법
KR20140082742A (ko) 암을 치료하는 방법
JP2018527308A5 (enExample)
CN103402517A (zh) 使用braf抑制剂的治疗方法
US20170105997A1 (en) Methods of treating cancer
US20140348819A1 (en) Methods of Treating Cancer
JP6855472B2 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
KR20170137886A (ko) 세리반투맙에 의한 병용 치료
JP2014529359A (ja) 投与および治療の方法
WO2014093750A1 (en) Method of administration and treatment
JP5834370B2 (ja) 組合せ
WO2019039390A1 (ja) 若年性骨髄単球性白血病治療薬
WO2015059677A1 (en) Methods of treating cancer
TWI906448B (zh) Kras g12c抑制劑在治療癌症中之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141031

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150929

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160426